锘� Indonesia approves Merck's COVID-19 pill for emergency use | Inquirer 黑料社

.simplePullQuote{--wpr-bg-dd6639c7-3e86-4afb-8b13-9e9550d6cd50: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-819c1c3e-5c54-4d1f-adde-5c824d52c42c: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-02470d4a-aae3-4b1a-be97-453dcc398337: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-8c69109b-3f83-4f9d-a9f4-1049b62ae7d3: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-a5406135-385f-4e17-a9dc-8d1f6067cf2c: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-3813179c-6fbd-4524-940d-01e1bd4638fd: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-9eb81cfb-d121-4264-bce5-4284f195e424: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-b8cfad4d-f211-4717-95c8-cc4b21ff2634: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-91ac6f60-01bd-4259-93b2-2b50eb35b633: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-43eb3ba0-5bfe-4947-8c0a-6559c3e3cc6c: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-6b14a80b-75bb-4499-b9b7-a3dcecef9f89: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-7d95e47c-5518-475b-8317-7361d7335cb0: url('/single2017/images/quote-texture.png');}.simplePullQuote{--wpr-bg-78b6e621-2e2e-4b72-973d-be84c1aeb835: url('/single2017/images/quote-2021.png');}.simplePullQuote{--wpr-bg-bc49193b-7b56-42dd-9eb6-48b6a7f336f1: url('/single2017/images/quote-texture.png');}.sib-flag{--wpr-bg-971e1b52-2d50-41f0-9f4b-2c391f47bd4c: url('https://static.brevo.com/images/flags.png');}.simplePullQuote{--wpr-bg-8eb53fc7-9e71-4d54-a120-f73326b2d454: url('/wp-content/plugins/simple-pull-quote/images/quote.png');}.rll-youtube-player .play{--wpr-bg-17c84f8e-fb7c-4558-b5c1-db454a59c32e: url('/wp-content/plugins/wp-rocket/assets/img/youtube.png');}#inq-banner-2021-FT-survey{--wpr-bg-2939f273-0203-434a-a9e2-be69b44db6e6: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_980x80-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-a47752bc-0db6-418b-8db3-8959c2031487: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_980x80-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-11951353-d38c-41ae-8b03-e09206363a9f: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_980x80-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-3a6ea0c1-9665-4758-907b-35a88620955e: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_375x100-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-06188dfd-56f1-49ba-b2a5-32e0c97e6dd0: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_375x100-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-b5297cc0-26db-417d-ac90-1ce7b06631a0: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_375x100-extended-ribbon.gif');}#inq-banner-2021-FT-survey{--wpr-bg-c3ba6b2e-2b1e-4b5e-b7cd-b7e16d41ffcf: url('https://www.inquirer.net/wp-content/uploads/2024/12/IQOS_375x100-extended-ribbon.gif');}#inqplus-cta-wrap{--wpr-bg-3331f0d5-5489-429a-9fac-e1c8a0193488: url('/single2017/images/inqplus-sub/inqplus-cta-bg1.png');}#newsletter-cta-wrap{--wpr-bg-9de0adce-b680-4645-abd3-b8d56ebc4aa0: url('/single2017/images/inqplus-sub/inqplus-cta-bg1.png');}

黑料社

FOLLOW US:

Subscribe to our daily newsletter

Your subscription could not be saved. Please try again.

Your subscription has been successful.

By providing an email address. I agree to the and acknowledge that I have read the .

Indonesia approves Merck’s COVID-19 pill for emergency use

Reuters / 12:49 PM January 14, 2022

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

JAKARTA — Indonesia has approved Merck & Co Inc’s COVID-19 antiviral pill molnupiravir for emergency use, the country’s food and drug agency said in a statement.

A batch of 400,000 pills had arrived in Indonesia, health minister Budi Gunadi Sadikin said this week. The pill was jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

READ NEXT

Legarda seeks special risk allowance for all health workers du...

Pfizer says it applied for Japan gov’t approval for oral...

EDITORS' PICK

5 die, 9 hurt as tourist van falls from a 50-meter ravine in Mt. Province

P15 million savings eyed from solar-powered Samar town hall

Four men nabbed in Angeles City drug den

MOST READ

5 die, 9 hurt as tourist van falls from a 50-meter ravine in Mt. Province

Dela Rosa accused聽of double standard

sports

entertainment

entertainment

newsinfo

5 die, 9 hurt as tourist van falls from a 50-meter ravine in Mt. Province

newsinfo

P15 million savings eyed from solar-powered Samar town hall

newsinfo

Four men nabbed in Angeles City drug den

TAGS: COVID-19, Indonesia, molnupiravir

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Disclaimer: Comments do not represent the views of 黑料社. We reserve the right to exclude comments which are inconsistent with our editorial standards. FULL DISCLAIMER

© Copyright 1997-2025 黑料社 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.